Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine

Vaccines

Carol Kao¹  Jens Wrammert¹  Inci Yildirim¹  Lalita Priyamvada¹  Evan J. Anderson²  Sarah Kabbani³  Mark J. Mulligan³  Yongxian Xu³  Nadine Rouphael³  Lilin Lai³  Lisa Jackson⁴  Johannes B. Goll⁵  Travis L. Jensen⁵  Heather Hill⁵ 

[1] .Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA;.Departments of Pediatrics and Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA;.Hope Clinic, Department of Medicine, Emory University School of Medicine, Decatur, GA 30030, USA;.Kaiser Permanente, Seattle, WA 98101, USA;.The Emmes Corporation, Rockville, MD 20850, USA;

关键词: mva;    smallpox;    follicular helper t cells (tfh), plasmablasts;    vaccinia;    antibody secreting cells;   

DOI  :  10.3390/vaccines8010069

来源: DOAJ

【 摘 要 】

Background: Vaccinia is known to induce antibody and cellular responses. Plasmablast, circulating follicular helper T (cT_FH) cells, cytokine-expressing CD4 T cells, and memory B cells were compared between subcutaneous (SC) and needle-free jet injection (JI) recipients of non-replicating modified vaccinia Ankara (MVA) vaccine. Methods: Vaccinia-naïve adults received MVA SC or by JI on Days 1 and 29. Vaccinia-specific antibodies were quantified by plaque reduction neutralization test (PRNT) and enzyme-linked immunosorbent assay. Plasmablast, cT_FH, and cytokine-expressing CD4 T cells were assessed on Days 1, 8, 15, 29, 36, 43 (cT_FH and CD4+ only) and 57. Memory B cells were measured on Days 1 and 57. Results: Of the 36 enrolled subjects, only 22 received both vaccinations and had evaluable specimens after the second vaccine. Plasmablasts peaked one week after each vaccine. Day 15 plasmablasts correlated with peak PRNT titers. cT_FH peaked on Days 8 and 36 and correlated with Day 36 plasmablasts. CD4+ peaked at Day 29 and one-third produced ≥2 cytokines. Day 57 memory B cells ranged from 0.1% to 0.17% of IgG-secreting B cells. Conclusions: This study provides insights into the cellular responses to non-replicating MVA, currently used as a vector for a variety of novel vaccines.

【 授权许可】

Unknown